Global Terbinafine Market By Type (Tablets, Topical Formulations (Cream, Gel, Spray, and Solution)), By Application (Fungal Infections Of The Finger Nails and Toe Nails, Tinea (Ringworm) Infections Of The Groin and Body, and others)), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019-2028

Published date: Apr 2022
Report ID: 29496
Number of Pages: 218
Format:

- 1. Terbinafine Market Introduction
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
- 2. Executive Summary
  - 2.1. Key Findings by Major Segments
  - 2.2. Top strategies by Major Players
- 3. Global Terbinafine Market Overview
  - 3.1. Terbinafine Market Dynamics
    3.1.1. Drivers
    3.1.2. Opportunities
    3.1.3. Restraints
    3.1.4. Challenges
  - 3.2. PESTLE Analysis
  - 3.3. Opportunity Map Analysis
  - 3.4. PORTER'S Five Forces Analysis
  - 3.5. Market Competition Scenario Analysis
  - 3.6. Product Life Cycle Analysis
  - 3.7. Opportunity Orbits
  - 3.8. Manufacturer Intensity Map
- 4. Global Terbinafine Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
  - 4.1. Global Terbinafine Market Analysis by Type: Introduction
  - 4.2. Market Size and Forecast by Region
  - 4.3. Tablets
  - 4.4. Topical formulations (cream
  - 4.5. gel
  - 4.6. spray
  - 4.7. solution)
- 5. Global Terbinafine Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
  - 5.1. Global Terbinafine Market Analysis by Application: Introduction
  - 5.2. Market Size and Forecast by Region
  - 5.3. Fungal infections of the finger nails and toe nails
  - 5.4. Tinea (ringworm) infections of the groin and body
  - 5.5. Tinea infections of the feet (athlete's foot)
- 6. Global Terbinafine Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
  - 6.1. North America
    6.1.1. North America Terbinafine Market: Regional Trend Analysis
    6.1.1.1. US
    6.1.1.2. Canada
    6.1.1.3. Mexico
  - 6.2.1. Europe
    6.2.1. Europe Terbinafine Market: Regional Trend Analysis
    6.2.1.1. Germany
    6.2.1.2. France
    6.2.1.3. UK
    6.2.1.4. Russia
    6.2.1.5. Italy
    6.2.1.6. Rest of Europe
  - 6.3. Asia-Pacific
    6.3.1. Asia-Pacific Terbinafine Market: Regional Trend Analysis
    6.3.1.1. China
    6.3.1.2. Japan
    6.3.1.3. Korea
    6.3.1.4. India
    6.3.1.5. Rest of Asia
  - 6.4. Latin America
    6.4.1. Latin America Terbinafine Market: Regional Trend Analysis
    6.4.1.1. Brazil
    6.4.1.2. Argentina
    6.4.1.3. Rest of Latin America
  - 6.5. Middle East and Africa
    6.5.1. Middle East and Africa Terbinafine Market: Regional Trend Analysis
    6.5.1.1. GCC
    6.5.1.2. South Africa
    6.5.1.3. Israel
    6.5.1.4. Rest of MEA
- 7. Global Terbinafine Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1. Market Share Analysis
  - 7.2. Company Profiles
  - 7.3. Rxlist
    7.3.1. Company Overview
    7.3.2. Financial Highlights
    7.3.3. Product Portfolio
    7.3.4. SWOT Analysis
    7.3.5. Key Strategies and Developments
  - 7.4. Novartis Pharma AG
    7.4.1. Company Overview
    7.4.2. Financial Highlights
    7.4.3. Product Portfolio
    7.4.4. SWOT Analysis
    7.4.5. Key Strategies and Developments
  - 7.5. Hanmi Pharm. Co.,
    7.5.1. Company Overview
    7.5.2. Financial Highlights
    7.5.3. Product Portfolio
    7.5.4. SWOT Analysis
    7.5.5. Key Strategies and Developments
  - 7.6. Bright Future Pharmaceuticals Factory
    7.6.1. Company Overview
    7.6.2. Financial Highlights
    7.6.3. Product Portfolio
    7.6.4. SWOT Analysis
    7.6.5. Key Strategies and Developments
  - 7.7. Taro pharmaceuticals usa
    7.7.1. Company Overview
    7.7.2. Financial Highlights
    7.7.3. Product Portfolio
    7.7.4. SWOT Analysis
    7.7.5. Key Strategies and Developments
  - 7.8. Aurobindo pharma
    7.8.1. Company Overview
    7.8.2. Financial Highlights
    7.8.3. Product Portfolio
    7.8.4. SWOT Analysis
    7.8.5. Key Strategies and Developments
  - 7.9. Breckenridge pharmaceutical
    7.9.1. Company Overview
    7.9.2. Financial Highlights
    7.9.3. Product Portfolio
    7.9.4. SWOT Analysis
    7.9.5. Key Strategies and Developments
  - 7.10. Gedeon richter usa
    7.10.1. Company Overview
    7.10.2. Financial Highlights
    7.10.3. Product Portfolio
    7.10.4. SWOT Analysis
    7.10.5. Key Strategies and Developments
  - 7.11. Genpharm
    7.11.1. Company Overview
    7.11.2. Financial Highlights
    7.11.3. Product Portfolio
    7.11.4. SWOT Analysis
    7.11.5. Key Strategies and Developments
  - 7.12. Dr. Reddy`s Laboratories
    7.12.1. Company Overview
    7.12.2. Financial Highlights
    7.12.3. Product Portfolio
    7.12.4. SWOT Analysis
    7.12.5. Key Strategies and Developments
  - 7.13. Glenmark generics
    7.13.1. Company Overview
    7.13.2. Financial Highlights
    7.13.3. Product Portfolio
    7.13.4. SWOT Analysis
    7.13.5. Key Strategies and Developments
  - 7.14. Invagen pharmaceuticals
    7.14.1. Company Overview
    7.14.2. Financial Highlights
    7.14.3. Product Portfolio
    7.14.4. SWOT Analysis
    7.14.5. Key Strategies and Developments
  - 7.15. Mylan pharmaceuticals
    7.15.1. Company Overview
    7.15.2. Financial Highlights
    7.15.3. Product Portfolio
    7.15.4. SWOT Analysis
    7.15.5. Key Strategies and Developments
  - 7.16. Orchid healthcare
    7.16.1. Company Overview
    7.16.2. Financial Highlights
    7.16.3. Product Portfolio
    7.16.4. SWOT Analysis
    7.16.5. Key Strategies and Developments
  - 7.17. Roxane laboratories
    7.17.1. Company Overview
    7.17.2. Financial Highlights
    7.17.3. Product Portfolio
    7.17.4. SWOT Analysis
    7.17.5. Key Strategies and Developments
  - 7.18. Teva pharmaceuticals usa
    7.18.1. Company Overview
    7.18.2. Financial Highlights
    7.18.3. Product Portfolio
    7.18.4. SWOT Analysis
    7.18.5. Key Strategies and Developments
  - 7.19. Watson laboratories
    7.19.1. Company Overview
    7.19.2. Financial Highlights
    7.19.3. Product Portfolio
    7.19.4. SWOT Analysis
    7.19.5. Key Strategies and Developments
  - 7.20. Wockhardt
    7.20.1. Company Overview
    7.20.2. Financial Highlights
    7.20.3. Product Portfolio
    7.20.4. SWOT Analysis
    7.20.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- Rxlist
- Novartis Pharma AG
- Hanmi Pharm. Co.,
- Bright Future Pharmaceuticals Factory
- Taro pharmaceuticals usa
- Aurobindo pharma
- Breckenridge pharmaceutical
- Gedeon richter usa
- Genpharm
- Dr. Reddy`s Laboratories
- Glenmark generics
- Invagen pharmaceuticals
- Mylan pharmaceuticals
- Orchid healthcare
- Roxane laboratories
- Teva pharmaceuticals usa
- Watson laboratories
- Wockhardt
Settings

Related Reports

Our Clients

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $5,999 $2,999 USD / per unit save 50%	Multi User $7,999 $3,499 USD / per unit save 55%	Corporate User $12,999 $4,499 USD / per unit save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 2,999)	Buy Now ($ 3,499)	Buy Now ($ 4,499)